Results of a first-in-human trial of LIB-01, a novel, first in class potential oral erectile dysfunction drug with unique pharmacodynamic properties. Presentation ESSM February 2025.
Results of a first-in-human trial of LIB-01, a novel, first in class potential oral ED drug with unique pharmacodynamic properties. Presentation SMSNA October 2024.
Results of a first-in-human trial of LIB-01, a novel, first in class potential oral ED drug with unique pharmacodynamic properties. Abstract SMSNA 2024.
Overview of nonclinical studies of LIB-01, a novel promising oral drug under development for treatment of erectile dysfunction. SMSNA November 2023.
The pro-erectile facilitator effect of LIB-01 in anesthesized Wistar rats is likely mediated via an NO/cGMP-independent pathway. ESSM February 2023.
Pro-erectile facilitator effect of LIB-01 in type 2 diabetic rats. October 2021.
Prolonged pro-erectile facilitator effect of LIB-01 in anesthetized Wistar rats. August 2021.
Libiguins A and B: novel phragmalin limonoids isolated from Neobeguea mahafalensis causing profound enhancement of sexual activity. DOI: 10.1055/s-0033-1360390
Semisynthesis of libiguin A and its analogues by trans-lactonization of phragmalin. DOI: 10.1021/jo500318w
Vi använder kakor (cookies) för att webbplatsen ska fungera på ett bra sätt och för anpassad marknadsföring.Du kan ställa in vad du vill acceptera och läsa mer om de cookies som används av oss här.
